Fresenius Medical Care AG (NYSE:FMS)’s share price fell 4.2% during trading on Friday . The company traded as low as $43.49 and last traded at $44.49, with a volume of 1,066,027 shares trading hands. The stock had previously closed at $46.42.

A number of research firms have commented on FMS. Berenberg Bank restated a “buy” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, August 9th. DZ Bank AG restated a “neutral” rating on shares of Fresenius Medical Care AG in a research report on Thursday, August 4th. Jefferies Group upgraded shares of Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research report on Friday, July 8th. Royal Bank Of Canada restated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Finally, Robert W. Baird restated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Monday, May 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $42.50.

The company has a market cap of $27.32 billion and a P/E ratio of 24.77. The stock has a 50-day moving average price of $45.02 and a 200 day moving average price of $43.44.

Fresenius Medical Care AG (NYSE:FMS) last released its quarterly earnings results on Tuesday, August 2nd. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.04. The business had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.54 billion. Equities research analysts anticipate that Fresenius Medical Care AG will post $2.01 EPS for the current fiscal year.

A number of institutional investors have added to or reduced their stakes in FMS. Comerica Bank raised its position in Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock worth $1,486,000 after buying an additional 1,798 shares in the last quarter. Bank of Montreal Can raised its position in Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock worth $2,373,000 after buying an additional 21,264 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock worth $4,493,000 after buying an additional 3,694 shares in the last quarter. Finally, Morgan Stanley raised its position in Fresenius Medical Care AG by 20.5% in the fourth quarter. Morgan Stanley now owns 685,338 shares of the company’s stock worth $28,675,000 after buying an additional 116,653 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.